CareLit Fachartikel
Progress in the Management of Advanced Renal Cell Carcinoma (RCC)
T. Q. T. Tong, D. Rohde, S. Peter · Aktuelle Urologie · 2010 · Heft S 01 · S. S57-S60
Dokument
1107143
CareLit-ID
Jahr
2010
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Abstract A more profound understanding in the pathophysiological mechanism of renal cell cancer has led to a shift in the treatment approach. Traditionally, cytokines were the frontline drugs, but recently this has transitioned to drugs interacting vascular endothelial growth factor (VEGF) related pathway. Sorafenib, sunitinib, bevacizumab, temsirolimus and everolimus have demonstrated clinical improvements in randomized trials. The purpose of this review is to summarise the current management of advanced RCC.
Schlagworte
renal cell cancer (RCC)
progression free survival (PFS)
Sorafenib
Sunitinib
Bevacizunab
Temsirolimus
Everolimus
Bevacizumab
Cytokines
Aktuelle Urologie
